• Huspy

  Participated · Series B · Jul 2025

  Huspy provides end-to-end digital tools that connect buyers, freelance agents, and banks to streamline property search, CRM, transaction support, and mortgage pre-approvals. It operates a network-based model (rather than owning inventory) where freelance agents access leads from marketplaces like Property Finder and Idealista while Huspy supplies CRM, transaction support, and integrated mortgage products through banking partnerships. The company says it captured 30% of the UAE mortgage market (25% in Dubai), has helped over 25,000 people buy homes, and facilitates over $7 billion in transactions. Revenue comes from commissions and success fees from agents and banks, and Huspy reports revenue growth of more than 10x since 2022 and claims over 20x year-on-year growth in Spain. It already operates in six Spanish cities and says it is one of the top three real estate companies in Valencia by transaction volume. Huspy plans continued expansion across Europe and the Middle East, including a launch in Saudi Arabia and a goal to operate in over 10 cities by the end of 2025. Huspy is a proptech company building a one-stop ‘super app’ that connects property search, purchase, financing and ancillary services (furnishing, maintenance, property management). Headquartered in Dubai with offices in Madrid and Abu Dhabi, Huspy places real estate agents at the center of transactions and has launched a ‘super app for agents’ in Madrid. It also operates in the Spanish mortgage market through two brands: Bayteca for residents and Mortgage Direct for non-residents. Huspy opened its first European “Agent Hub” in Madrid and has plans to expand to additional Spanish cities as part of a broader European rollout. Since its creation three and a half years ago, the company has facilitated more than €5.5 billion in housing transactions and helped over 13,500 people purchase properties. The firm aims to double its activity in Europe and become the largest home‑buying company in Europe and the Middle East. Huspy offers a suite of digital solutions for buyers, property agents, and mortgage brokers, including a home finance product that scrapes banks weekly to provide mortgage quotes and loan locks in minutes. It also operates a property marketplace that lists verified properties (integrated via agency CRMs), lets users book visits, and completes transactions on customers' behalf. The company claims to process $2 billion in annualized GMV, is growing revenue 25% month-on-month, closes transactions three times faster than other platforms, and reports a conversion rate north of 90%. Huspy monetizes by charging banks 1% per mortgage transaction and charging real estate agencies 2–3% for closed transactions. Founded in 2020 by Jad Antoun and Khalid Ashmawy and operating across Dubai and Madrid, Huspy acquired Dubai-based Home Matters in January to ramp up growth. The company says it is the market leader in the UAE and plans to double down on growth in the UAE and Spain, expand into other parts of Europe, and invest in technology and product development.

• Hedera-22

  Participated · Equity · Aug 2024

  Hedera-22 is a Belgian spin-off from the University of Liège developing an intelligent platform to discover new biomolecules with biopesticide activity. Founded in 2015 by ULiege scientists and professors, the company transitioned from supplying bioinformatics services to actively discovering novel natural compounds. Since 2023 it has been executing the Ab-Initio project to build an advanced natural product discovery platform that integrates molecular biology technologies with proprietary predictive bioinformatics tools based on machine learning. The company says the first version of the Ab-Initio platform will be available in early 2026 and has filed a patent for its prediction method. The recent financing of about €2 million — a capital increase from shareholders combined with subsidies from the Walloon Region — will fund R&D, team expansion and further development of its bioinformatics tools. Hedera-22 plans to commercialize a large library of identified molecules for the bioprotection sector via licensing and partnerships and aims to position itself as a world leader in discovery of novel biopesticidal compounds. Founded in 2015 as a spin-off of the University of Liège, Hedera-22 provides tailored bioinformatic services for healthcare and biotech industries while developing its own discovery platform. The company combines environmental microbiology and bioinformatics to accelerate identification and production of novel biomolecules for human medicine and the agro-industry. A proof of concept resulting in production of thaxtomin, a promising bioherbicide, attracted strategic interest from Globachem. Hedera-22 plans to set up laboratories at Sart-Tilman, acquire cutting-edge equipment, and consolidate its team to speed development and commercialization. The startup raised more than €1 million in its first financing round to fund these activities. Globachem has become a key shareholder as part of the deal.

• Minagro

  Participated · Equity · Apr 2023

  Minagro is a Louvain‑la‑Neuve, Belgium–based developer of green products for crop care, founded in 2019 by Arnold de Maere. Its core offerings are agrochemical ingredients and formulations based on sustainable raw materials and proprietary green and specialty chemistry technologies. Products include in‑can preservatives, adjuvants, solvents and bio‑stimulant actives aimed at improving crop protection and nutrition while reducing environmental impact. The company conducts R&D and research activities in confirmed proprietary technologies and has initiated collaborations with regional innovation clusters and research centers. Minagro plans to reinforce its R&D assets in bio‑based and specialty chemistry, develop collaboration projects, and widen its agrochemical ingredient product line. The company recently raised funding to continue market validation and scale up ingredients in its current portfolio.

• BioStrand

  Led · Equity · Jun 2020

  BioStrand is a Belgian startup developing a platform to analyze genetic data. Its technology aims to detect analogies and genetic variations to drive innovation in precision medicine, biotechnology and agriculture. The company says the underlying technology was developed over the past seven years. BioStrand was created in February 2019 and is led by CEO Dr Ingrid Brands with Dr Dirk van Hyfte as CTO. The company intends to use recent funds to commercialize its platform. The article does not report revenue or user metrics.

• Biotalys

  Participated · Series C · Jul 2019

  Biotalys develops a new generation of protein-based biocontrol solutions built on a proprietary technology platform, aiming to combine chemical-like performance with the safety profile of biologicals. The company has a broad pipeline addressing crop pests and diseases across the value chain, and its lead biofungicide, BioFun-1, has shown consistent high efficacy in global fruit and vegetable trials. Biotalys was on track in 2020 to submit BioFun-1 registration dossiers later that year and expected a U.S. launch in 2022 followed by global introductions. The firm is advancing a protein-based bio-bactericide program targeting bacterial diseases including cankers, blight and spots. Financially, Biotalys has raised €61 million ($66m USD) to date from specialist international investors and supplements that financing with non-dilutive research grants. The company was founded in 2013 as a VIB spin-off and is based in Ghent, Belgium. Biotalys is developing a new generation of protein-based biocontrols intended to provide high-performance crop protection with the safety profile of biologicals. Its technology platform has produced a pipeline of products with novel modes of action addressing pests and diseases across the value chain, from soil to plate. The company positions its protein-based solutions for both pre- and post-harvest applications, aiming to combine chemical-like consistency with biological safety. Proceeds from the Series C will fund development, regulatory registration and commercial-scale production of its lead biofungicide and further expansion of the discovery platform. Biotalys plans to launch its first biofungicide in 2022 in the U.S. fruit and vegetables market and to accelerate development of its broader pipeline. Founded in 2013 as a spin-off from VIB, the company is based in Ghent, Belgium and had raised €61 million to date. AgroSavfe is developing a new generation of protein-based biocontrols based on its proprietary AGROBODY™ Foundry Platform to protect seeds, crops and food from farm to fork. Its product candidates include biofungicide and bioinsecticide candidates that the company says combine chemical-like performance with the clean safety profile of biologicals and leave no residues. The company reports more than 100 field trials since 2017, with its most advanced biofungicide demonstrating strong, competitive performance versus synthetic chemicals. Planned uses include pre- and post-harvest applications to reduce food loss and improve food quality along the value chain. The company intends to use recent funding to support development, registration and commercial-scale production of its biofungicide and bioinsecticide products and to strengthen its organization. AgroSavfe scheduled the launch of its first biofungicide for 2022 in the U.S. fruit and vegetables market, followed by launches in Europe and other regions. AgroSavfe is a Ghent, Belgium-based agro-biotech spin-off from VIB that develops Agrobodies, small proteins designed and formulated to specifically bind to essential target molecules of crop pests and diseases. The company is led by Managing Director Marnix Peferoen. Agrobodies are positioned as a new generation of biopesticides and are the firm's core product. AgroSavfe extended its Series B financing round to €11m. The company intends to use the funds to accelerate development of its Agrobodies and to roll out the international registration process. Earlier investors include Agri Investment Fund, Biovest, Gimv, Globachem, Madeli Participaties, PMV, Qbic and VIB, with Sofinnova Partners joining the extension. AgroSavfe is a Gent, Belgium-based green biotech spin-off of the VIB department of the Free University of Brussels. The company develops innovative formulations of crop protection products using its proprietary Agrobody technology. It will focus on research and development of those formulations. Led by CEO Marnix Peferoen, AgroSavfe is based in the VIB Bio-incubator in the Ghent technology park and employs nine people. The company raised €5m in funding to support its activities. The articles do not disclose revenue, prior rounds, or whether the funding was equity or debt.

No current team members are available.